Kursausbruch nach oben bei Elite Pharmaceuticals! - 500 Beiträge pro Seite

[sekko1982]

Am Freitag gab es einen wichtigen charttechnischen Ausbruch nach oben.




Es wird dieser Tage spekuliert, dass Elite Pharmaceuticals postive Studienergebnisse über ihre medizinischen Forschungsarbeiten veröffentlichen wird.

Laut einem Bericht ist ein Umsatzpotential von 1 Milliarde USD pro Jahr vorhanden. Zitat:

" The Stamford, Connecticut-based drugmaker will ask a joint panel of U.S. advisers next week to back a new OxyContin formula that may prevent abusers from crushing the pill or dissolving it in alcohol to release several hours of narcotics at once. Pain Therapeutics Inc., Alpharma Inc. and Elite Pharmaceuticals Inc. predict a $1 billion market for alternatives they're developing even if Purdue beats them to pharmacies. "

Quelle:

http://www.nipcweb.com/Purdue_Rivals_Oxy.pdf

Aktuelle Marktkapitalisierung lediglich 20 Millionen USD.

In US-Foren herrscht große Aufregung. Es ist mit weiteren Kurssteigerungen zu rechnen.

http://messages.finance.yahoo.com/mb/ELTP.OB


http://investorshub.advfn.com/boards/board.aspx?board_id=151…


Schlusskurs am Freitag war 0,191 USD. Nächster Widerstand bei 0,24$.




Neben Washington Mutual meiner Ansicht nach die interessanteste US-Aktie für die kommende Woche.

[sekko1982]

!

Dieser Beitrag wurde moderiert. Grund: Korrespondierendes Posting wurde entfernt

[sekko1982]

Lt. barchart.com wird Elite Pharmaceuticals mit STRONG BUY bewertet!


http://barchart.com/quotes/stocks/ELTP

[sekko1982]

Aus dem US-Forum:

Our Indicators are Flashing a Signal Here;

this was an oversold condition within an uptrend buy signal

targets generated by Fib extension and Gann are $0.28 thru $0.295

this is also an Elliot Wave 5 up, we are getting Fib based extension estimates of $0.327 and 0.46$

Wave 5 is itself a 5 part wave

part 2 of it is violent selling that may take out all of the initial thrust (hopefully no more than 78.6%)IT IS DESIGNED TO SCARE YOU

YOU CANT SELL

When 3 hits, its massive.....

Look for higher prices from here..

Quelle:


http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

[sekko1982]

Antwort auf Beitrag Nr.: 41.538.286 von sekko1982 am 22.05.11 13:54:08

Es gibt sogar einige US-Anleger, die Kurse um die 1,00 USD-Marke für möglich halten.


http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

Klar, wenn man bedenkt, dass die zukünftigen Medikamente von Elite Pharmaceuticals ein Umsatzpotential von 1 Milliarde USD haben. Derzeitige Marktkapitalisierung beträgt lediglich 20 Millionen USD. Sehr interessante Ausgangslage!

[sekko1982]

Antwort auf Beitrag Nr.: 41.538.422 von sekko1982 am 22.05.11 14:57:04

Am Freitag ging es nachbörslich mit einem 250.000 Stücke-Kauf weiter nach oben: 0,1967 USD.


http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[brocklesnar]

hallo Sekko,
vielen Dank für den Hinweis werde mir mal den Wert genauer anschauen

gruß brocki

[sekko1982]

Antwort auf Beitrag Nr.: 41.538.813 von brocklesnar am 22.05.11 18:19:15

Grüß Dich brocki

Hier noch ein Chart. Alle drei dort aufgeführten charttechnischen Indikatoren mit Kaufsignalen.

[sekko1982]

Antwort auf Beitrag Nr.: 41.538.830 von sekko1982 am 22.05.11 18:27:08

Hier der Link:

http://stockcharts.com/h-sc/ui?s=ELTP&p=D&yr=0&mn=3&dy=0&id=…

[sekko1982]

Elite Pharmaceuticals hat angemeldete 12 Patente und es kursieren Gerüchte, dass in Kürze eine positive Erfolgsmeldung veröffentlicht wird.

five United States patents and have pending applications for five United States patents and seven foreign patents

http://www.elitepharma.com/patents.asp

Nicht umsonst ist der Kurs am Freitag rund 50% gestiegen!

[sekko1982]

Antwort auf Beitrag Nr.: 41.538.867 von sekko1982 am 22.05.11 18:37:04

Ergänzend dazu:

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[sekko1982]

Guten Morgen

Bei den Amis wird sogar um Mitternacht heiss diskutiert:


http://messages.finance.yahoo.com/mb/ELTP.OB

[sekko1982]

Die Ask-Seite in Berlin steht schon bei 0,19€. Daher verstärken sich meine Erwartungen, dass wir heute in USA Kurse um die 0,30 USD sehen werden.

[schokie]

eine interessante aktie sekko viel. komm ich noch günstig an der otc rein

[workstock]

Rechne ohne Meldung mit einem Rücksetzer. War bereits am Freitag zum Handelsschluß mit ein Rücksetzer erkennbar. Einige werden hier ohne fundametale Begründung Gewinne mitnehmen.

[sekko1982]

Antwort auf Beitrag Nr.: 41.540.437 von schokie am 23.05.11 09:35:45

Grüß Dich schokie,

ich habe meine USA-Kauforder bereits eingegeben und warte nun den Start um 15:30 Uhr ab.

Viel Erfolg allen Interessenten!

[sekko1982]

Antwort auf Beitrag Nr.: 41.540.472 von workstock am 23.05.11 09:40:03

Also ich kann im Freitag-Chart, auch gegen Handelsschluss, keinen Verkaufsdruck erkennen. Wichtig war, dass die 0,18 USD halten. Schlusskurs war bekanntlich 0,191 USD.




Jeder ist sein eigener Kapitän. Viel Erfolg!

[schokie]

Antwort auf Beitrag Nr.: 41.540.497 von sekko1982 am 23.05.11 09:42:56

wo hast du dich denn auf die lauer gelegt wenn ich fragen darf

[sekko1982]

Antwort auf Beitrag Nr.: 41.540.553 von schokie am 23.05.11 09:47:55

Kauforder eingegeben mit Limit 0,22 USD.

[schokie]

das wären 0,157 hier in d
0,19 ask ist weit über pari.. ca 50% aufschlag dann lieber otc

[sekko1982]

Antwort auf Beitrag Nr.: 41.540.607 von schokie am 23.05.11 09:53:14

Ja sehe ich auch.

Ich werde mir auch die vorbörslichen Daten ganz genau anschauen und ggf. meine Kauforder nach oben anpassen. Aber 0,22 USD wäre mir natürlich viel lieber!

[feel99]

Antwort auf Beitrag Nr.: 41.540.636 von sekko1982 am 23.05.11 09:55:45

Hast du schon mal die vorbörslichen Taxen angeschaut? Die Phantasie beruht hier nur auf möglichen Ergebnissen und dann daraus reslutierenden Umsäten.... Ist die Frage wohin hier die Reise geht. Oder nur ein Zock?? Hab noch kein Gefühl, du hast dich mit dem Wert mehr beschäftigt, vielleicht mal eine kurze Info danke.

[schokie]

bis jetzt an die 0,21 ran

[feel99]

Antwort auf Beitrag Nr.: 41.542.801 von schokie am 23.05.11 15:41:04

Na ja jetzt erst mal Gewinnmitnahmen

[schokie]

war schon immer so ich hab mich mal um 0,16 positioniert

[feel99]

Da bin ich ja mal gespannt was das Teil heute noch drauf hat. Ging nicht ganz bis 16 und bis ich alles eingebegen hatte, habe ich welche zu 0,181 bekommen. Wäre schön wenn es so auf 26 bis 28 ct gehen würde.

[feel99]

Antwort auf Beitrag Nr.: 41.540.497 von sekko1982 am 23.05.11 09:42:56

Wieso schreibst du dass du deine Kauforder in USA eingegeben hast und nachdem es runter geht, dass du bei 16 nachkaufen willst, passt irgendwie nicht ganz zusammen?

[Jim_Panse]

Alle möglichen Threads voll spammen und dann so ein Rohrkrepierer...

[geldmanager]

Antwort auf Beitrag Nr.: 41.543.135 von feel99 am 23.05.11 16:15:58

bei dem handelsvolumen, u über 9o% gewinn!
ist das sehr gewagt hier weiter groß zu investieren?

[Stammzelle01]

Ich will ja nichts sagen aber der Verlauf heute könnte noch richtig gut enden.

Sollten hier die grünen Vorzeichen wiederkommen könnten zum Tagesschluß die 0,25 Dollar noch ereicht werden.

Nichts für ungut aber ein Kauf heute morgen zu Kursen um die 0,19 Euro war sicherlich nicht ganz so schlau aber ich schätze das auch derjenige seinen Einstandskurs widersehen wird diese Woche.

Ich wette der Tag endet gruen ind en USA für ELTP

[Blankerhanz]

Antwort auf Beitrag Nr.: 41.544.318 von Stammzelle01 am 23.05.11 19:17:31

try again

[workstock]

ELTP off of the 50 DMA here. Entry about .12 or .13. We like our picks to have a good shot at a 100% gain and this one has a strong possibility of hitting the recent .26 high which will give us the 100%. ELTP also has a solid chance at busting through the recent high of .26 after testing it. There is a lot going on with the company as far as their pharmaceutical production goes.

This buy issue from .12/.13 today after a 2 day pullback from .19. This pullback was because some shares were added to the OS. You can read about it in today’s news.

We’ve been very consistent with our past stock picks, and we never give out to much information. If you want to know more about the company. It’s easy enough to find.

We’ll keep you posted on movement and changes. Good luck!


http://thepennystockblog.com/blog/stock-pick-eltp

[workstock]

admin
says:
May 25, 2011 at 6:49 am 10.75 is a nice price, its a little below the 50 dma and the 50% pullback from .26 would be .13. so TA wise the .12/.13 are solid. At your lower price I would have to hesitate on a buy because the stock would be under the 50 signaling at least a minimal breakdown, leading me to watch what happens next.

Great little stock but I don’t thing the ceiling is .26, have a feeling it could run to .75 or so but that is NOT a prediction. Trade it properly but it has all the potential of a takeover candidate as well. Lots of good things here.

[feel99]

Für ein hier so unbekanntes Unternehmen sind über 2.000.000 € an Handelsvolumen nicht schlecht, da können sich hier zig Firmen was abschneiden

[feel99]

Antwort auf Beitrag Nr.: 41.540.636 von sekko1982 am 23.05.11 09:55:45

Hallo Sekko bist du hier noch dabei? Oder hast du das Schiff schon verlassen.

[sekko1982]

Antwort auf Beitrag Nr.: 41.569.112 von feel99 am 27.05.11 18:47:46

Elite Pharma ist ideal zum Traden. Derzeit stehe ich an der Seitenlinie und bin in einem anderen Wert aus dem Social Network-Bereich investiert.

[huenerhaufen30]

Endlich kommt mal Schwung rein :-)

[feel99]

Glaube dass dieser Wert richtig Potential hat und nur noch eine gute News braucht. Diesmal bin ich dann aber am Anfang dabei und muss nicht überlegen ob ich bei 100 % Steigerung noch reingehe oder abwarte. Das ist das Hauptproblem bei Werten die ins laufen geraten.

[feel99]

Warum interessiert sich eigentlich niemand für diesen Wert?? Drüben werden recht ordentliche Größenordnungen gehandelt und viele warten dort auf den Ausbruch. Der Wert fällt nicht und bleibt recht konstant und wenn ich mir die sonstigen Werte hier bei WO so anschaue ist das hier eine echte Alternative.

[feel99]

Wir haben es hier mit einem soliden Unternehmen was stetig am wachsen ist zu tun. Und sowie die ersten Übernahmegerüchte aufkommen geht es ganz schnell richtig 1$ nach oben. Das wird hier in den nächsten Wochen noch eine ganz spannende Geschichte. Allemal besser als die ganze Inso Buden die hier gezockt werden.

[feel99]

Antwort auf Beitrag Nr.: 41.573.018 von sekko1982 am 29.05.11 16:59:18

Hallo Sekko, du stehst anscheinend noch an der Seitenlinie, ich glaube es geht bald los und dann wird diese Firma eine Perle die nicht nur ein kurzes Strohfeuer ist. Ich schätze hier entsteht was langfristiges und ich bin wirklich gespannt, wie lange die deutschen noch brauchen um das zu merken. In den Ami Bords ist die ganz klare Meinung strong buy.

[sekko1982]

Antwort auf Beitrag Nr.: 41.635.985 von feel99 am 11.06.11 10:42:17

Mahlzeit,

ich stehe derzeit an der Seitenlinie. Elite Pharma ist eine sehr interessante story und wenn nur einer deren Patente einschlägt, dann sind mehrere 100% nicht ausgeschlossen. Bis dahin jedoch eher ein Wert zum Traden mit "speculative buy"-Charakter.

[feel99]

Antwort auf Beitrag Nr.: 41.639.907 von sekko1982 am 13.06.11 15:26:18

Da bin ja mal gespannt ob du den optimalen Einstieg findest. Denn wenn hier nur eine News von die vielen die in der Pipeline stecken kommt, geht es hier richtig los. Mir fällt momentan kein Wert ein, der einen sicherern Boden hat und mehr langfristige Perspektive. Kann mir gut vorstellen hier länger zu halten, denn wenn es in Richtung 1 $ geht werden viele Kasse machen und vielleicht die langfristige Entwicklung nicht mitnehmen. Wir werden sehen.

[workstock]

Könnt ihr auch mal inhaltlich etwas dazu geben. Ständig wird hier von Pipeline, Patenten, Übernahmen und Perspektiven gesprochen. Das muss man doch mal zusammenfassen können und hier reinschreiben?

[workstock]

tangerine Member Profile tangerine Share Sunday, June 05, 2011 7:53:27 PM
Re: None Post # of 7519
Updated analysis including links and recent events. This is my best attempt to collect all and present all the date. Please feel free to add to this

This is not your typical penny stock. I am not a big time trader. Most of my holdings have been mutual funds and stock of larger corporations and mostly safe plays. When I found Elite in December I thought it was a good risk. Now with the previous conference call, deal with Epic, recent operational profitability, and conversion to a manufacturing mindset, I know that most of the risk is now gone. As Dianne from IR (Investor Relations) ends up saying to me every time I call her, and I paraphrase ; “This company acts like a big company because it used to be one and plans to be one again”.

How many penny stocks can you say that about? Most penny stocks have minimal revenue, tons of R&D costs and you are hoping beyond hope that some Phase 1 or 2 trials result will be positive, or that they sign a customer to avoid bankruptcy. All hedging or awaiting some miracle. Elite went through that stage and almost declared bankruptcy in 2009. They had offers to be bought out but were able to drastically cut costs and stay in business until their first operationally profitable quarter. That means they can start paying off their bills. This is where they were at the beginning of the year.

Where are they now?

Much closer than ever to becoming the company they set out to be when they were spending 10s of millions of dollars on R&D to perfect and patent their abuse resistant line of drugs and their 24 hour time release line of drugs. This is Elites Core plan, they have more than 7 patents, several just assigned in Europe and Canada, and in final review with the USPO. Abuse resistance was re-submitted on 5/17 for another review and extended release was re- submitted on 3/17.

12/640,344 (patent#) - ABUSE-RESISTANT ORAL DOSAGE FORMS AND METHOD OF USE THEREOF

10/951,978 (patent#) - Extended Release of Opiods.

These patents are not just for Oxycontin which has been in the news and is very controversial due to the high rate of abuse and addiction. The patent claims are actually for numerous drugs. Both hard to make 24 hour formulations and abuse resistance formulations. Notice there really isn’t a 24 hour Oxycontin pill available and the current abuse resistant ones are having problems. Also note that Elite is in PH3 with these drugs. The 10s of millions that they spend from 2001-2009 got them this far. They have European partners awaiting PH3 it would seem based on the website and conference calls.

http://www.elitepharma.com/investor_relations.asp?goto=330

Always keep in mind that these drugs are already FDA approved on their own merits. What is in question is Elites ability to maintain plasma levels and they have shown the patent pending ability to do this. That is the focus of their patents and what makes them unique and possibly a leader in the market.
Some links for interesting data on this:

Notice who Elite is named alongside and the revenue from these drugs

http://www.businesswire.com/news/home/20110412007011/en/Rese…

http://www.elitepharma.com/product_pipeline.asp

http://seekingalpha.com/article/251469-pain-therapeutics-opt…

http://www.nipcweb.com/Purdue_Rivals_Oxy.pdf

Must read article “Alpharma Inc. and Elite Pharmaceuticals Inc. predict a $1 billion market for alternatives they're developing even if Purdue beats them to pharmacies.”

Also note that Oxycontin becomes a generic drug in 2013 so Elite will get their either way but the patents give them exclusivity of course.

Look up the patents for yourself (patent #s above) and you can read all for yourself:

http://portal.uspto.gov/external/portal/!ut/p/c5/04_SB8K8xLL…

So the above is the homerun. What happens if Elite has to go through more rounds and resubmissions with the patent office and FDA? They almost went bankrupt chasing this outcome until they implemented a new business plan. This plan as highlighted in the February conference call and put out for all to see is actually simple. Utilize their state of the art manufacturing facility to make generic drugs.

In fact they are doubling their manufacturing capacity now.
Epic already made drugs at this facility which is DEA and FDA approved. No easy feat and not that common. It means they can make controlled substances and ultimately will be making their unique and patented formulations of these drugs.

Where is the immediate revenue going to come from?

It started with Lodrane and as we saw, they were operationally profitable on about 4 million dollars. They only have 16 Elite employees. Epic manufactures many of the drugs out of the facility. Lodrane was a good moneymaker for Elite. However, in March the FDA pulled about 500 drugs off the shelves, giving a 6 month timeline for compliance. Elite will have to stop making the drug.

However, the active ingredients have been in effect for over 40 years and ECR who markets Lodrance for Hitech (HITK) has initiated a lawsuit against the FDA stating that Lodrane has the same active ingredients as Dimetapp and is not “grase”

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2011/05/…

“Last Friday, Petitions for Review were filed with the U.S. Court of Appeals for the District of Columbia Circuit on behalf of ECR Pharmaceuticals (“ECR”) and Laser Pharmaceuticals, LLC (“Laser”) requesting that the Court review and set aside FDA’s March 3, 2011 decisions (here and here) that certain marketed unapproved drug products are not Generally Recognized as Safe and Effective (“GRASE”). (Both FDC Act § 505(h) and FDA’s regulations at 21 C.F.R. § 514.235(b) permit a direct appeal to an appellate court within 60 days after the entry of a relevant FDA order.) “

So what happens if they totally lose Lodrane? Elite took care of this with their deals with Epic. Epic pharmaceuticals are now tied directly to Elite based on the recent deals.

http://www.epic-pharma.com/

http://investing.businessweek.com/research/stocks/private/sn…

http://www.reuters.com/finance/stocks/ELTP.OB/key-developmen…

So based on this, we see 8 ANDAs being produced at Elites facility whereby Elite gets 15% of the profits. Based on research it appears some of these drugs maybe be already produced at Elite’s facility. There is also much speculation that Elite and Epic will form a reverse merger of sort. Conversion of preferred shares to common is often a predecessor for type of deal.

Elite was awarded Hydromorphone and Phentermine from Epic for them to produce on their own. They are partnered with TAGI. They also received Naltrexone ANDA from Mikah Pharmaceuticals LLC

http://www.healthcarepackaging.com/archives/2010/09/elite_ph…

“Pursuant to the License Agreement, TAGI Pharma will market and sell four Elite generic products (the "Products") in the United States, Puerto Rico and Canada. Elite will receive a license fee and milestone payments and Elite will manufacture the Products. The license fee will be computed as a percentage of the gross profit, as defined in the License Agreement, earned by TAGI Pharma as a result of sales of the products. The license fee is payable monthly for the term of the License Agreement. The milestone payments will be paid in 6 installments. The first installment was paid upon execution of the License Agreement and the remaining installments are to be paid upon FDA approval and initial shipment of the products to Precision Dose. Two of the Products, hydromorphone hydrochloride, 8 mg, and naltrexone hydrochloride, 50 mg, are approved products recently purchased by Elite and currently being transferred to Elite. Collectively, the brand products and their generic equivalents had total annual sales of approximately $120 million in 2009.”

Phentermine has a value of ~40 million per year with about 10 other manufacturers. They received this from Epic

http://americanpharmaceuticalreview.com/ViewArticle.aspx?Con…

Also note the following recent increase and notoriety for both Phentermine and Naltrexone

While a key ingredient in Elites abuse resistance technology, it is now found to be a remedy for Crohns disease as well as MS and AIDs.

http://www.lowdosenaltrexone.org/

http://en.wikipedia.org/wiki/Low-dose_naltrexone

I believe there are 5 manufacturers of this drug currently
And Phentermine has been recently at the forefront as an effective diet pill. This is not a new pill but it is receiving more and more notoriety. Do a google search and see.

http://thechart.blogs.cnn.com/2011/04/10/study-weight-loss-c…

These are the drugs we know about. What else is coming in the immediate future? Based on the pipeline there are two more undisclosed ANDA drugs in development. We also know they are working on another ANDA with Epic and TAGI as described in the links above.

There is also a CT order in place which will be somewhat revealed in June I believe. This confidential treatment relates to a new or one of the above drugs.

http://quotemedia.10kwizard.com/cgi/image?repo=tenk&ipage=75…

http://messages.finance.yahoo.com/Business_%26_Finance/Inves…

If you go back through the SEC filings you will find that this is most likely related to another deal with Mikah pharmaceuticals and per Elite’s Investor Relations, done to maintain a competitive advantage. Basically you do not want other companies knowing what you are planning to release/develop. My guess is it is another ANDA. Also note that the Mikah VP who signed some of these agreements is also a special consultant to the CEO of EPIC. More on this in a bit

http://www.postjobfree.com/resume/hp88ni/qa-medical-technolo…
So how many drugs are coming out of Elites facility in the current and near term?

Phentermine, Naltrexone, Hydromorphone, Epics 8, New Epic ANDA, New Mikah ANDA? CT order product(s), 2 undisclosed from pipeline
Hopefully Eli 216 and 154.

Also in March, Elite won $500k and the right to produce Methadone with an approved ANDA

http://www.marketwatch.com/story/elite-announces-settlement-…

So what are the negatives and outlook for success?
Losing Lodrane hurts because it was what kept Elite in business over the last couple years. The new drugs can more than make up for it considering just Phentermine, Naltrexone and Hydromorphone represented 160 million in revenue in 2009. While I believe Naltrexone and Phentermine’s value has increased due to the recent notoriety and Naltrexone being used for other serious diseases, just 5% of the 160 million is double what they had for Lodrane.

Also note a couple things:

ECR and HITK began the FDA process for Lodrane in 2010. Their current lawsuit it for a stay of an additional 6 months to complete the FDA required submissions and the argument is that they were not given due process under the law and there is no imminent threat to the public. Makes sense considering the FDA is allowing it to be sold for an additional 6 months. Also note that Dimetapp uses the same exact active ingredients. My understanding is that ECR is spending millions to complete the FDA requirements. Lodrane is worth ~15 million/year to them. There are some other scenarios that have been floated about relabeling and other measures but that is not 100% clear to me. Also they may be able to produce the instant release version. Also not clear to me.

Dilution – This is a scary word for investors like me. However, the “dilution” has been a conversion of preferred shares to common shares. Some believe this may be a precursor to a merger with Epic. The share count did not change; Elite did not sell shares to get cash for operations. Simply put, the preferred shares became common shares and eliminated the need to pay dividends of ~$700k per year. Also note these are not Elite or Epic management selling shares but investors. In fact Elite insiders have actually purchased shares in the March timeframe.

Trellus and Morris selling shares – Both of these are old investors selling pieces of their holdings that they purchased at a much higher price. No one except them knows why they are selling. Trellus has been known to sell shares almost monthly. They have sold a few million this year including about2.5 million recently. Their holdings are still ~17.5 million shares.
Morris was an elderly businessman, I believe in his 80s. His shares were put in a trust for himself, his family and foundation. It appears that ~ 15/20 million shares were sold, primarily from his foundation and his wife and kids.

No one knows why they sold but it is important to know that neither him nor Trellus should be selling based on inside information. They helped finance Elite but are not “insiders”. I have a feeling it is related to tax write-offs and paying bills and retirement plans. I believe Trellus paid over $1 per share. That’s a big write off and worth a lot more than the current share price.

I am very encouraged by how well the PPS has held up despite these sales. It always seems that there has been a buyer for these shares as they were sold. I am not sure what is going on here but it looks like serious accumulation of this company. I saw it when we had 60 million volume days and again recently. These cheap shares have been in demand. Notice the failure to delivers on this stock, naked shorting etc. They have been having a hard time covering without shanigans. Elite’s Lawyers are aware of the failure to deliver issues.

Debt-like just about every small pharma company, Elite has debt incurred from their facility and their years of R&D. It appears they are now in position to begin paying that debt off.

Other items I have heard but are not accurate – Elite is not paying their bondholders, Elite is going bankrupt, no money in generics, no money in pain medications, it’s a scam company, etc…

Call Dianne at Elite for the full history on the company. It’s a real American manufacturing company, operationally profitable and a pipeline with almost unlimited potential. It is also not hard to understand their business plan. No miracle required here.
So who benefits from Elite?

This is the most important question. Follow the money; who stands to make money if Elite succeeds to the highest degrees? Who wants to see the PPS soar?

Elite CEO is paid a nominal fee but mostly in stock. My understanding is Jerry Treppel had a major investment in Elite and took over as CEO to ensure success of the company and protect his investment. Remember they almost went bankrupt in 2009 timeframe. New CEO and management implemented a smart and highly feasible business plan to bring in manufacturing revenue and have the partners to do it.

Epic and Elite execs are major shareholders. The two companies as described above are now tied together. Epic can ensure Elite is successful in the near and long term. This is what I believe spurred the recent rise in PPS more than anything. Actual company insiders have purchased stock. Epic can make Elite as successful as they want by supplying new ANDAs and keeping costs very low. We are seeing this already.

I have read numerous rumors that there could be a reverse merger between Epic and Elite. Epic does own and has access to enough shares to probably make this happen. The conversion of the preferred D shares is seen by some as a sign that this could happen. There are other tidbits regarding the June timeline being required to make this happen as it represents a specific timeline from other deals. This is not 100% clear to me but the data is out there to be investigated.

I do see it as a real possibility. Epic and Elites relationship is very symbiotic and Epic could get a ton of cash out of it. The PPS would certainly soar and the two companies could be a force due to their efficiency, unique product pipelines and generic manufacturing capacity. Elite makes 24 hours drugs that are effective and this tech can be used with many drugs. Elite has received buyout offers in the past but that was when their worth was at an absolute low.

Once bankruptcy was off the table, and the relationship with Epic is understood, much of the risk associated with this penny stock was taken off the table for me. Now they are executing on their business plan right in front of us.

Elite CEO has not been secretive about the desire to get back on the big boards, Nasdaq and a reverse split is not part of the plan to get there.

What lies in the immediate future?

Long term, this company is a no brainer to me. Without a threat of bankruptcy, the patents pending and the generic possibilities coming online now, especially in hard to formulate and controlled substances, the revenue is there and should only greatly increase.

This is just the beginning.

If you think about it, all of Elites products are at the forefront of news due to increased coverage over the concern of abuse of prescription drugs (Eli – 216, 154 and other formulations), danger and feasibility of diet drugs, increased success for new applications of Naltrexone and of course increased demand for generic drugs.

The timing is absolutely perfect. This explains why they are expanding their facility.

Hydromorphone and Naltrexone should be shipping at any time now. They are noted as pending launch on their website. Phentermine shipped in quick order so I have been expecting these two to ship soon

CT order is going to be somewhat revealed during the next conference call is also my understanding

Earnings report ~(7/7/11) should present outstanding numbers. Deal with Epic, TPN lawsuit, Lodrane manufacturing continued during this time and should have been done to meet the 6 months allowed by the FDA. I am expecting that to be larger than normal to ensure product availability through the allotted 6 months.

Also any milestone payments from Epic and TAGI. Epic s 8 drugs are likely in process. I noted multiple ANDAs being awarded to Epic recently.

We should also hear back on the ECR lawsuit with the FDA which seems like they have a very good case but I am not an attorney and do not know how this will play out.

And of course the patents should be very close to being reviewed with an announcement of the results. Dates of re-submission noted above. Seems each resubmission can take several months for review. The 24 hour patent especially should be soon since it was sent in on 3/17 I believe.

These are just the recent items we know about.

I am not in the pharma business nor am I in the financial business. This is the best of the data from doing my own due diligence and investigation. I suggest everyone do their own research and contact IR for more info.

I do know that this company has solid growth potential as a generic drug manufacturing company. I also know that their patents are for drugs and formulations that have potential that is measured in billions of dollars. 24 hour time release, abuse resistant drugs could easily be a preferred choice in the pain market. Elite seems to be the only company in position to actually make this possibility a reality especially with certain drugs like Oxycontin. The timing is now due to the current attention in the media and from the government.

If this stock was $1 would you be surprised at the growth potential? Maybe? At 15 cents, the only conclusion I can come to is that it is a very undervalued company but the volume we have seen shows me that people have noticed. I don’t believe this is an “if” company any longer but just a matter of “when”.

Here is my very conservative approach to calculating PPS using very low P/E of 12

Lodrane – 4 million
Naltrexone and Hydromorphone =120 million, figure 6.5 competitors (5 Naltex, 8 for Hydro), 50% of the revenue taken in goes to Elite = 120/6.5/2 = 9.2million

Phentermine – 40 million, 10 distribs, assume 10%*50%=1 million

Epics 8 drugs – Since we don’t fully know what the drugs are, we will assume each drug profit avg 2 million. 15% * 16 million = 2.4 million

So, very conservatively 4+9.2+1+2.4= 16.6 million dollars with approximately 250 million shares
= .066 x 12 = .79 cents for a very conservative pps.

I think Naltrexone will be bigger due to Crohns, Aids and MS usage
I also think Phentermine will be more due to recent press noted above.

And none of this takes into account all the patent pending drugs, new ANDAs pending, deal with Mikah etc

[workstock]

von tangarine aus dem ihub board:


Here is my very conservative approach to calculating PPS using very low P/E of 12

Lodrane – 4 million
Naltrexone and Hydromorphone =120 million, figure 6.5 competitors (5 Naltex, 8 for Hydro), 50% of the revenue taken in goes to Elite = 120/6.5/2 = 9.2million

Phentermine – 40 million, 10 distribs, assume 10%*50%=1 million

Epics 8 drugs – Since we don’t fully know what the drugs are, we will assume each drug profit avg 2 million. 15% * 16 million = 2.4 million

So, very conservatively 4+9.2+1+2.4= 16.6 million dollars with approximately 250 million shares
= .066 x 12 = .79 cents for a very conservative pps.

[zpo]

.

Press Release Source: Elite Pharmaceuticals, Inc. On Friday June 24, 2011, 8:30 am EDT

NORTHVALE, N.J., June 24, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP - News), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations and generics with high barriers to entry, announced today the Company will host a conference call on Thursday, June 30, 2011 at 4:30 PM EDT to review fourth quarter and year-end 2011 results of operations and provide an update on recent business developments Company executives will also conduct a question and answer session following their remarks.

http://finance.yahoo.com/news/Elite-Pharmaceuticals-Inc-pz-6…

.

[zpo]

.

bis jetzt ja ganz nett, was

.

[feel99]

Das geht mir hier jetzt fast etwas zu schnell.....

[zpo]

.

wieso zu schnell ?

kein gap-up zu Freitag

schön gestiegen

3 stunden um die .19 seitwärts

dann weiter

jetzt um die .20

bis Do an die .30 sollte schon gehen, was

.

[zpo]

.

Ganz frisch:

Press Release Source: Elite Pharmaceuticals, Inc. On Wednesday June 29, 2011, 8:30 am

NORTHVALE, N.J., June 29, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP - News) today announced that it has entered into a commercial Manufacturing and Supply Agreement with ThePharmaNetwork, LLC, and its wholly owned subsidiary, Ascend Laboratories, LLC (together "TPN"). Under the terms of the agreement, Elite will perform manufacturing and packaging for TPN's Methadone Hydrochloride, 10 mg tablets.



Elite will be compensated at an agreed upon price for the manufacturing and packaging of the products.



Jerry Treppel, Chairman and CEO of Elite commented, "We are pleased to assist TPN with the launch and commercialization of their Methadone product and in light of the recent action by the FDA with the Lodrane family of products, this agreement will help Elite buffer the impact by providing a new revenue stream."

.

[zpo]

.





.

[zpo]

.

das war nix

.

[workstock]

woh, kauf in berlin für 0,10€ = 127,27%. wenn dass die OTC bestätigt, :-))

[pflicht]

Ich bin etwas investiert in Elite. Es scheint mir ein
aussichtsreiches Investment zu sein. Nur vermute ich,
daß ein längerer Atem notwendig ist. Mein Durchschnittskurs
beläuft sich aber auf ca 0,15 US $.
Beim jetzigen Kurs von 0,10 $ überlege ich mir noch etwas
nachzukaufen.
Es wäre schön, wenn sich hier noch ein paar Elite investierte
einfinden könnten zum Meinungsaustausch.

pflicht

Bin investiert in
Apri
IPCI
Eltp.ob

allerdings jeweils nur in kleinem Rahmen.

[feel99]

Ich finde die Firma richtig interessant, bin schon seit über 2 Monaten dabei, habe etwas zu hoch gekauft, aber wenn die Bude sich etabliert kann es ein Unternehmen werden, was einige $ pro Share wert sein kann.
Ich werde egal wie der Kurs steht nicht verkaufen. Das Teil behalte ich einfach mal.

[pflicht]

Elite scheint auch ein interessanter Kanditat zu sein.
Obwohl ich nicht recht durchsteige, welche Produkte diese
Firma in der Pipeline hat ist mein Gefühl positiv.
Auf Gefühle kann man aber leider nicht wetten.

Auf yahoo war gestern ein Beitrag zu lesen(mit einem Link auf CCN-money forecast) wo ein Kurs in 12 Monaten von 4.50 $ geschätzt wird.
Das wären 4.000 %. Eine solche Steigerung halte ich für nicht möglich. Trotzdem höre ich sowas natürlich gerne.

Bei einem Kurs von 0.40 $ würde ich eigentlich schon aussteigen.

pflicht

[cheeben]

http://www.reuters.com/finance/stocks/ELTP.OB/key-developmen…

[frankpic]

Zulassung:

http://www.elitepharma.com/investor_relations.asp?goto=340

[schiedo]

Neue Zahlen sind da.
Kursausbruch nach oben ???

[Hobbyaktien]

Kann mir jemand bitte hier mal ein paar Infos auf deutsch zu dieser Aktie zukommen lassen??

Für was für ein Medikament haben sie die Zulassung bekommen??

Wie viele weitere Produkte sind noch in der Pipeline usw.

Wie lange reicht das eigenkapital der Fa. Elite noch?

Gibt es schon Partner für die Vermarktung??

[Hobbyaktien]

Antwort auf Beitrag Nr.: 42.825.283 von Hobbyaktien am 29.02.12 13:03:50

Also ich bin hier erstmal eingestiegen, sieht alles ganz gut aus, zumindest auf dem ersten Blick, ist hier noch jemand investiert??

Kann mir noch jemand meine Fragen aus dem Beitrag vorher beantworten?

[feel99]

Ich bin hier schon ein paar Monate mit ein paar Stücken dabei und die Firma ist in der Entwicklung von Schmerzmedikamenten tätig. Die haben ca. 10 bis 20 Produkte in der Entwicklung und vor 3 Wochen einen 5 Mill Kredit bekommen um in Ruhe weiter zu arbeiten. Wenn nur 1 oder 2 dieser Medikamente greifen geht es hier höllisch ab. In den Ami Bords wird in diesem Fall mit einer Entwicklung bis 4 $ gerechnet. Kann aber noch dauern. Hab die Teile einfach zum liegen lassen und wenn es schief geht auch nicht so schlimm. Außerdem verkaufen die schon 2 Produkte und haben Lizensvereinbarungen womit sie aktuell Geld verdienen.

[Hobbyaktien]

Antwort auf Beitrag Nr.: 42.834.223 von feel99 am 01.03.12 16:04:07

Danke fürs Feedback. Ich werde den wert auch mal langfristig halten, mal sehen was passiert.

Es ist immer schon gut, wenn Umsätze erzielt werden, bei einem Pharmaunternehmen.

Sind die anderen die hier al geschrieben haben auch noch drin oder haben die schon geschmissen?

[feel99]

Antwort auf Beitrag Nr.: 42.837.160 von Hobbyaktien am 01.03.12 22:22:46

Keine Ahnung hab seit ein paar Monaten keine Postings mehr gesehen.
Auf Seite 2 ist aber ein Link für ein Ami Forum mit Google Übersetzer kannst du da einigermaßen erkennen was gerade so in diesem Wert los ist.

[Hobbyaktien]

Antwort auf Beitrag Nr.: 42.834.223 von feel99 am 01.03.12 16:04:07

Gibt es denn schon medikamente die weiter fortgeschritten sind in der Entwicklung??

Also auch Medikamente die schon in der 2 Phase oder 3 Phase sind??

Wie lange reichen denn die 5 Mio??

[schiedo]

Zitat von Hobbyaktien: Danke fürs Feedback. Ich werde den wert auch mal langfristig halten, mal sehen was passiert.

Es ist immer schon gut, wenn Umsätze erzielt werden, bei einem Pharmaunternehmen.

Sind die anderen die hier al geschrieben haben auch noch drin oder haben die schon geschmissen?

Ich habe mit hohen Verlust geschmissen, bin bei GALE eingestiegen und den Verlust in 2 Tagen aufgeholt.
Beim Kauf von GALE gibt es bis zum 8.März je eine Aktie von der Schwester Fa. kostenlos dazu Spin off....

Keine Werbung nur eine Emfehlung !

[Hobbyaktien]

Antwort auf Beitrag Nr.: 42.852.572 von schiedo am 05.03.12 16:57:03

Man ist das hier ein scheiß Ding.

Da passiert ja gar nichts. Immer nur am schwanken zwischen 0,09 - 0,10 Usd.

Und heute sogar mal kurz unter 0,09 USD. ist doch zum kotzen.

Werde den Wert wohl langfristig im depot behalten.

[Hobbyaktien]

Antwort auf Beitrag Nr.: 42.889.436 von Hobbyaktien am 12.03.12 18:59:15

Hat sich ja am ende nochmal gut erholt zumindest bis 0,095 USD.

Aber warum so viele zu 0,09 USD verkaufen ist mir ein Rätsel, aber die Nachfrage scheint dort auch ziemlcih groß zu sein.

schaun wir mal, wie es weiter geht, eine gute News bei nur einem Medikament bei den vielen in der Entwicklung und Ruck Zuck steht der Kurs ein paar 100 % höher als jetzt.
`
Erstmal gute N8, allen Mitlesern.

[Hobbyaktien]

sieht doch ganz gut aus heute,, würd emich ncht wundern, wenn es noch auf die 0,10 usd heute geht.

Let´s rock.

[feel99]

Hab das Teil schon fast 9 Monate und hab es einfach liegen gelassen, aber anscheinend tut sich jetzt mal langsam was. Wenn die jetzt so langsam ins Geld verdienen kommen könnten die Dollar Prognosen ja irgendwann noch eintreffen.

[pflicht]

Gibt es noch investierte in Elite?
Wäre an einer regelmäßigen Diskussion interessiert.

Pflicht

[pflicht]

Suche weitere "ELITE" -aktionäre zum Meinungsaustausch.
Mir scheint, Elite dürfte ein gutes Invest sein.
Derzeitiger Kurs $ 0,10
Kursziel : $ 0,30 in den nächsten 6 Monaten.
auf yahoo kursieren Kursziele von $ 1 bis Jahresende.

pflicht

[Eltp]

Hallo zusammen,

anliegend ein Artikel von "Seeking Alpha" zu der jüngsten Entwicklung von Elite. Der Zug fängt langsam an zu Rollen. Es scheint an der Zeit zu sein einzusteigen ..... :-)

Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.

In my previous article published on May 28th titled Actavis: Abuse-Deterrent Opioid Connections<http://seekingalpha.com/article/1463281-actavis-abuse-deterr… I noted connections and relationships to watch for between Actavis (ACT<" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/act> and several companies. As it turns out, several of these companies have played a role in the re-emergence of the relatively unknown Elite Pharmaceuticals (ELTP.OB<." target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/eltp.ob>. This article will examine these recent events and evaluate the opportunity this presents to investors. In my opinion, this is an incredible comeback story that will not go unnoticed much longer.

About seven years ago, Elite Pharmaceuticals traded on the AMEX, was popular among investment firms, and had a bright future with controlled release and abuse resistant opioid technologies. However, mistakes by management, coupled with the down turn in the economy left the company short of being able to attain their goals and on the verge of bankruptcy. An interesting read is this 2006 interview<http://www.elitepharma.com/resources/Elite.pdf> in the Wall street Journal with the former CEO Bernard Berk. Elite was an innovator but ran out of time and money when the market crashed shortly thereafter. The technology was there but the financial sustainability was not. A stock that used to trade for dollars now trades for eight cents.

But that is starting to change.

What has happened since May 28th?
· In June they announced sales of their existing drugs resulted in a record quarter.<http://www.elitepharma.com/investor_relations.asp?goto=362&g…
· In August they announced senior management from Actavis has taken over key roles at Elite.<http://globenewswire.com/news-release/2013/08/05/564476/1004…
· In addition in August they announced numerous FDA approved drugs have been added to Elite's growing pipeline.<http://www.elitepharma.com/investor_relations.asp?goto=361&g…
· In their most recent earnings conference call Elite announced they were on the verge of getting their abuse deterrent products into the final stages needed to garner FDA approval.
· During the Rodman and Renshaw Conference<http://www.wsw.com/webcast/rrshq23/eltp/>, CEO Nasrat Hakim noted that they have been approached by several companies regarding Elite's technology including meetings with a CEO the day before and the Chairman of a major pharmaceutical company two weeks prior.
· Elite previously cited in their filings "doubt as to our ability to meet our business objectives and to continue as a going concern." Their most recent 10q removes that language.

This is now a company with a 10 million dollar financing deal<http://www.elitepharma.com/investor_relations.asp?goto=356&g… in place, nineteen FDA approved drugs to be manufactured, approximately eighteen more in the pipeline in various stages with numerous partners, and are about to enter studies to submit for a 505b2 NDA, twice daily abuse-deterrent Oxycontin/Oxycodone product. Additional abuse-deterrent products are also scaled up or in development<http://biotuesdays.com/2013/08/06/elite-eyes-home-run-in-abu… such as a once daily Oxycontin/Oxycodone and a Morphine product. New senior leadership with extensive experience to take these products from the development phase to the approved phase was announced several weeks ago. And this is where we will begin to look at these relationships I note above and what I believe is the New Elite Pharmaceuticals.

The biggest and most recent catalyst was the hiring of Nasrat Hakim, former Global Vice President at Actavis and Alpharma<http://online.wsj.com/article/PR-CO-20130805-903837.html>… This has set the stage for Elite to take the next step in their comeback. In addition to extensive leadership and experience, Nasrat Hakim also brought with him 12 approved ANDAs (Abbreviated New Drug Applications), one pending approval, effectively merging his private company Mikah Pharmaceuticals with Elite. Elite also hired Doug Plassche as executive Vice President of Operations<http://globenewswire.com/news-release/2013/08/12/566117/1004… also from Actavis.

For competitive reasons Elite is not releasing the names of the products they are receiving from Mikah until a material event, but a quick check of the FDA orange book and simple deductive reasoning greatly substantiates speculation that these are a few of the products identified in the FTC approved divestiture agreement between Actavis and Watson<http://www.ftc.gov/os/caselist/1210132/121015watsonactavisdo… Elite's press release notes that two of these products are in markets with only one other competitor obviously indicating this to likely be the case.

However, all of these approved generic drugs, some with little competition and additional products in Elite's pipeline (Close to 40 in total now) are not why Nasrat took over. Here is what he said in a recent conference call when asked about why Elite's stock price is so low<http://seekingalpha.com/article/1639802-elite-pharmaceutical…:" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/article/1639802-elite-pharmaceutical…:

The technology itself is sound; we haven't changed it much for years. But it's how we managed it in the 2000s and 95 and 2002 was the issue. In order for Elite to survive eventually they started making products. So now we are measured on our earnings. We are an R&D company; if Elite did not have the manufacturing capability and they were only an R&D facility with this great technology, the stock would be 10 times higher than it is today, that's my personal opinion.

When you start measuring an R&D facility with a superior technology that could bring in oxy twice a day with naltrexone to the market in a short period of time, that could bring oxy once a day, that could go into other avenues such as Embeda working on morphine sulfate and other opioids. If we look at that and look at the market that it could generate the stock will be in a different place. Unfortunately we are sitting here listening to our earnings of a million and two and even when we bring Mikah's products and we bring in millions of dollars more, if you guys are happy with that I will consider myself a failure.

I did not come here to have an R&D start a manufacturing company that's producing $20 million, $30 million a year. I was working for a company that's making billions of dollars per year. My annual budget was the price of Elite times 10. I am here for our R&D superior technology and this is the primary focus of my heart and soul and that's my commitment to the stockholders.

Have you heard many CEOs say that increasing revenues five to ten times should be considered a failure? Nasrat is correct and when you begin to look at the market place and see how other companies are doing in this space, you begin to see that Elite is very well positioned. Elite is currently being judged on its current revenues and not on all the products and revenues to soon come from these approved, unnamed products and certainly not from their R&D and products in development.

Further strengthening Elite's position; several key companies in this field have had great difficulty proving their products would be abuse deterrent or viable. Endo pharmaceuticals (ENDP<," target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/endp>, failed to prove to the FDA<http://www.fiercepharma.com/story/fda-nixes-endo-petition-pr… that their Oxymorphone product was a significant deterrent to abuse. More recently, Acura Pharmaceuticals (ACUR<" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/acur> failed to show in trials<http://www.reuters.com/article/2013/08/26/acura-study-paindr… that their version of the pain killer Percocet exhibited a significant decrease in "likeability" by abusers crushing the product. Pfizer's Embeda was recalled<http://www.pharmalive.com/big-pain-pfizer-embeda-recalled>…." target="_blank" rel="nofollow ugc noopener">http://www.pharmalive.com/big-pain-pfizer-embeda-recalled>…. Pain Therapeutics (PTIE<" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/ptie> and Durects (DRRX<" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/drrx> Remoxy faces a long uphill battle<http://www.fiercebiotech.com/story/pfizer-spares-painkiller-…

Drug addicts are creative and determined enough to get around these features. Even Purdue's recently approved and considered to be abuse-deterrent product can likely be defeated via instructions found on the internet using an microwave and conventional oven. With a street value of up to $60 or more per pill<http://www.sacbee.com/2013/09/09/5719799/new-research-shows-… there is a significant interest in defeating these measures and in an information and social media age, it does not take long for these techniques to be shared within the drug user community.

Could this happen to Elite? The amazing answer is probably not. Elite's product is not based on trying to create a physical barrier to abuse. Elite's technology is based on a pharmacological approach<http://www.elitepharma.com/How_AR_Tech_Works.pdf> to eliminating the euphoric effects drug abusers seek. The ingredients and efficacy of this approach are already accepted and understood. This approach is the same concept used by Pfizer (PFE<," target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/pfe>, has been approved by the FDA in Pfizer's Embeda product, and noted in the FDAs guidelines<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat… creating these type of products. It is also interesting to note that Nasrat Hakim was with Alpharma during the development of Embeda.

The key difference is being able to manufacture a stable product that does not release a significant amount of Naltrexone. Pfizer's Embeda was recalled due to stability issues<http://www.pharmalive.com/big-pain-pfizer-embeda-recalled>… and has yet to return to market.

Elite's patented technology has shown in Ph1 and Ph2 trials to not release Naltrexone and crush studies have been done which showed a significant reduction in Euphoria<http://www.elitepharma.com/investor_relations.asp?goto=280&g… This is to be expected as Naltrexone is well known to reverse the effects of Opioids. So if an abuser attempts to manipulate Elite's extended release opioid products, they will not get the euphoric high they seek and may even experience mild withdrawal symptoms.

What sets Elite's product apart is that this is a truly modular concept. Elite uses a patented two bead approach<http://www.elitepharma.com/How_AR_Tech_Works.pdf> and formulation inside a capsule. One bead contains the agonist (opioid) and the other bead contains the antagonist (Naltrexone). These tiny beads use essentially the same materials and are indistinguishable from each other. So if you can create an opioid bead and you can create a Naltrexone bead that will not leak a significant amount of Naltrexone, you can adjust these two items to suit any opioid.

Pfizer is also working on an Oxycontin product using the same concept as Embeda. These products attempt to wrap the opioid around a core of Naltrexone which is a more complicated manufacturing process.

Where other companies need to develop and test each formulation based on altering the physical characteristics of the pill, Elite essentially needs to adjust the opioid type and dosage of each bead which is far less complicated to develop. Could Elite effectively create an entire line of extended release opioid products in a relatively short amount of time? The amazing answer is they absolutely could and Elite's Chairman Jerry Treppel has noted that this is his vision. Here is what Nasrat Hakim noted in the recent conference call when asked why he is so confident in Elite's technology.<http://seekingalpha.com/article/1639802-elite-pharmaceutical…

I will give only two simple little examples and I'll try my best to simplify it as much as I can. When I joined the company or before I even joined the company, I've had the opportunity to have a close relationship with Elite. So I looked at some of the data and presentations that they have. Elite developed a once-a-day anti abuse, actually once-a-day oxy and made the (inaudible), put them on stability for three years and the data after three years was rock solid Using the same technology that we could actually go to the market with.

Furthermore they took that same once-a-day tablet and ran clinical trials on 19 people and they ran it against a competitor and our results were better at least according to my analysis and I am knowledgeable in this area, were better than the competitors and we presented all of that data to an expert that we had here yesterday to help us with the filing.

So when I see that it has been proven first in manufacturing on a large scale and second on stability over time of up to three years and third on a human trial, it is self-evident that the technology works.

Okay; second the issue came that the twice-a-day may have a better market for that. So that technology was also developed, they placed on stability. We had six months stability on the latest slots with the API and that data is also rock solid.

Our (inaudible) polymers are the same story, and the beauty of this technology is it has two separate beads, and each one of them functions independently, but when inter-mixed cannot be separated and both of them separately have been proven to work in the human trials of 19 people on stability and in manufacturing.

This is why I am wondering why hasn't this been done in the past and that's why I said earlier that, I don't think historically when the data was generated in the early 2000, the R&D folks that were working on this took the necessary business risk and both went to the market instead scientist sometimes like to play around more and add more examinations and look at more bio studies and examine more data and we ended up where we are at.

I truly believe in this technology and that is why I merged my company in it and became a part of it.

So it is obvious that management believes in this technology and the company has put themselves in position to reap the benefits from all of the products in the pipeline. One thing both Nasrat and Jerry certainly have in common is a belief in the future of Elite Pharmaceuticals, demonstrated by taking salary almost entirely in stock. Jerry Treppel also provided the company a one million dollar unsecured line of credit<http://globenewswire.com/news-release/2012/12/10/510445/1001… As it turns out, Nasrat Hakim was already one of Elite's largest stock holders owning 11 million shares prior to his arrival.

But how should investors begin to place a value on the company? I also have to ask myself, what would this company cost to buy? What price would they demand if a major pharma came in to buy them for their abuse-deterrent technology? I actually think this is a likely scenario as large pharmas have much to lose<http://www.dailyfinance.com/2012/07/10/the-fdas-plan-to-redu… as the FDA begins to favor generics<http://www.healthcareglobal.com/administration/big-pharma-ra… that have abuse deterrent features in what is a seven billion dollar market. Here is a simple bullet list of Elite's assets and potential revenue drivers.
1. Eight launched products, 8th due now to launch
2. Thirteen ANDAs, (Eleven Approved, two pending approval)
3. Three Abuse Deterrent Opioids (Twice-daily and Once daily Oxycodone, Morphine) ~$3 Billion dollar market
4. Once-a-day Oxycodone (Partner interested in Europe)
5. 505B2 product MIK001 in development with Mikah
6. Ownership of approximately 10% of Novel Laboratories
7. Expected to trial an allergy product similar to 24 hour Lodrane product - Financial partner willing
8. Partnered - Hi-tech (HITK<" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/symbol/hitk> generic - 100 million branded product
9. Undisclosed NDA-product approved overseas -Hong Kong Partner with multiple overseas FDA approved facilities.
10. Eight generic products partnered with Epic Pharmaceuticals.
11. Nine Patents and four more pending

A quick note regarding Elite's 10% stake in Novel Labs. This asset includes Novel's marketing arm Gavis and Novel has many products on the market, recently received approval for the "plan B" pill otherwise known as the "morning after" pill. They are also in development of numerous first to file products. For additional information, you can read more about them in Elite's 10k, Novel's website<http://www.novellabs.net/>and this article<http://www.smallcapnetwork.com/Elite-Pharmaceuticals-ELTP-Mo… They have recently acquired a controlling interest in Indian Pharma company Wintac<http://www.indiainfoline.com/Markets/News/Wintacs-board-appr…

Elite is not a cash rich company. Their revenues are getting very close to paying their bills outside of R&D expenses and they should be completely cash flow positive by the end of their 2014 fiscal year. Based on recent filings, Elite's operations has a run rate of about $700k per quarter outside of those R&D activities which of course are heavily focused on the massive abuse deterrent opioid products. With about $230k in cash and $600k still available from the current Chairman's line of credit, Elite can basically run their manufacturing business for break even on the products recently launched and just beginning to gain market share. Q4 of their last fiscal year saw a company record $1.5m in revenue, and this past Q was at $721k which was lower due to issues since resolved and discussed on the CC. As these products continue to grow and the many others are launched, these revenues are going to rapidly increase.

While Elite may not have a lot of cash, they also have little debt, about $4 million total. It is a remarkably low number for a company with this much potential, technological experience and assets. Previous shareholders paid for it all.

Elite has a $10 million dollar financing deal in place with Lincoln Park Capital Fund, LLC which is based on the current PPS. As of the last 10q, only $394k was used. As Elite's value grows, the financing rate follows the PPS, limiting the dilutive effect to shareholders. However as noted by Nasrat Hakim at the Rodman and Renshaw conference, they have been meeting with a number of interested parties including a CEO and a Chairman from major pharmaceutical companies. They are looking to partner for both marketing and trials in a profit split type of arrangement. Elite has the resources to move forward with current financing, but having a major partner now will obviously accelerate their growth. Many investors are waiting for Elite to simply sell their growing investment in Novel Labs as well.

So what is the downside? After all this is a penny stock. There are really only two items that I note as having any consequence. One is the share count and structure which includes authorized share count of up to 690m shares. However if all these shares came to bear, you would still looking at only a 56m market cap. Elite's latest filing shows approximately 400 million common shares and fully diluted of about 580 million shares. Based on the current stock price, this represents a market cap of only 32 million dollars which in my opinion makes it remarkably undervalued.

The other item is Elite's notice of default on their bond from the trustee of NJEDA starting in 2009. Elite has put a proposal out there to resolve this issue for a number of years but it is still an overhang that does not seem to concern anyone as interest payments have been made for a number of years now. Here is what it says in the recent filings.

In addition, the Company has received Notice of Default from the Trustee of the NJEDA Bonds as a result of the utilization of the debt service reserve being used to pay semi-annual interest payments due on September 1st and March 1st of each year. The debt service reserve was first used to make such semi-annual interest payments on March 1, 2009 and has been utilized for all semi-annual interest payments due since then, with the Restricted Cash Interest Payments constituting such payments.

The Company has replenished all amounts withdrawn from the debt service reserve for the payment of semi-annual interest payments, as required, and in accordance with the applicable terms and conditions of such replenishments.

There are approximately forty products in Elite's pipeline now, the large majority not launched and those that have launched are relatively new to the market. Revenues are continually increasing and can really only trend much higher as these products are introduced. Then consider Elite's approximate 10% ownership stake in Novel. Now add in the R&D and abuse-deterrent products that brought recognized industry executives to take over top leadership positions, take salary in stock, and merge their company into Elite and you would have a difficult time finding a comparable company with a market cap less than 200 million dollars.

Elite's new CEO believes that if Elite was being evaluated simply on their R&D alone, the stock would be many times higher than it is today. Unfortunately the company's difficult past, the stigma and manipulation and games associated with OTC stocks, and being evaluated based on current revenues have kept the price down but certainly not the company itself. Elite will soon be making many announcements related to these trials and products. Many are due for approval, launch, partnerships for marketing and trials for 2.7 Billion dollar Oxycodone as noted in the Rodman and Renshaw Presentation. Of course the most anticipated event will be the trial results which based on the technology, previous trials and the science behind them, should pass with flying colors. It is the best opportunity I have seen to jump on an R&D play with a high chance for success and expect many times return on your investment.

The CEO is looking to turn this into a billion dollar company and is putting his reputation, time and money on the line. And even if he is a failure, you would still see a profitable drug company with 30 plus approved drugs, numerous ANDA and NDA partnerships, and a growing asset in their stake in Novel Labs. Elite is not only close to achieving the lofty goals that had investors excited years ago, they may greatly surpass them.

I don't believe this opportunity is going to go undiscovered for much longer and at a 33m market cap, the upside is absolutely incredible and there is not much downside at current levels.

Disclosure: I am long ELTP.OB<http://seekingalpha.com/symbol/eltp.ob>. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

[Eltp]

... gibt es hier noch andere Community Member, die in Elite investiert sind. Ich beobachte diese Aktie seit ca. fünf Jahren mit all ihren Höhen nd Tiefen. Aus meiner persönlichen Sicht ist jetzt der Zeitpunkt gekommen, an dem die Arbeit der vegangenen Jahre beginnt Früchte zu Tragen. Sowohl das Management wurde mit hochqualifizierten Kräften aus der Brache besetzt, als auch die finanzielle Basis des Untenehmens Schein gesichert. Die Meldung Cash Flow positive wird jederzeit erwartet Bd die Clinical Trials für die Marktfreigabe der Abuse resistant Technology ART beginnen in ca. Zwei Monaten. Der Markt für das erste Medikament hat in de USA ein Volmen von ca. 2,5 MRD Dollar. Die Technologie kann aufgrund ihrer zwei Komponenten auf viele andere abhängig machende Mediamente übertragen werden.

....würde mich freuen, wenn es weitere Info zu dieser Aktie von anderer Seite gibt.

[due-diligence]

Es schein sich in der Tat etwas bei dem Papier zu tun. Der Aktienkurs an der US Börse ist unter steigendem Volumen in den vergangenen Tagen um ca. 40% gestiegen. Ich werde weiter ein Auge drauf haben.

[Eltp]

... offensichtlich eine erste Konsolidierung nach fünf Tagen steigender Kurse. Bin gespannt, ob die Aktie sich oberhalb der 0,10 USD halten kann.

[Eltp]

... und wieder 20%Kursgewinn an einem Tag bei steigendem Volumen.... :-)

[due-diligence]

Naltrexone wurde nach dem FDA Approval erstmals an einen der Distributoren ausgeliefert. Zudem stellt dieses Medikament einen Teil der der beiden Layer der Abuse resistent Technology dar. Das Unternehmen scheint auf einem guten Weg. Es bleibt spannend!!!



Elite Pharmaceuticals, Inc. Announces First Shipment of Generic Naltrexone Hydrochloride


Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of naltrexone hydrochloride 50 mg tablets under the License, Manufacturing and Supply Agreement with its sales and marketing partner, triggering a milestone payment. Elite's sales and marketing partner will distribute the product as part of a multi-product distribution agreement.
Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. For the calendar year 2012, Revia and its generic equivalents had total U.S. sales of approximately $16 million according to IMS Health Data.

"With the shipment of naltrexone, Elite has now launched seven products in less than two and a half years," commented Nasrat Hakim, Elite's President and CEO. "The Company has executed the strategic plan on schedule. This plan now includes an additional thirteen products, eleven of which are approved, and are prioritized for commercialization pending manufacturing site transfer."

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, eleven approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

CONTACT: For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
[e-mail]
www.elitepharma.com

[Eltp]

Die Aktie fängt langsam an Freude zu machen. 100% in einer Woche. Die Firma scheint kurz vor Cash Flow positive zu stehen. Zudem gibt es eine Menge weiterer Themen, die sich in den kommenden Wochen entscheiden werden.

[due-diligence]

Vor ca. zwei Jahren gab es schon einmal einen Lauf der Aktie. Auch damals war ich dabei. Aus meiner Sicht war die damalige Situation jedoch eine grundlegend andere.

Im Gegensatz zu damals hat das Unternehmen jetzt einen CEO, der bis vor kurzem Bein dem drittgrößten Generikahersteller der Welt (Actavis) in leitender Funktion beschäftigt war. Auf der Investoren Conference R&R vor gut einer Woche wurde von Nasrat Hakim (CEO) auf die kommenden Meilensteine verwiesen.

- Start der finalen Studie um die Freigabe der FDA für die Abuse resistent Technology 505B2 für einen $2.7Milliarden Markt für oxycontin zu erreichen.
- Bekanntgabe laufender Gespräche mit den CEOs der großen Pharmakonzerne für ein Partnermodell im Rahmen der Vermarktung des Medikamentes.
- Suche eines Partners für die Vermarktung der 13 neuen Medikamente des ELTP Produkt Portfolios.

Aus meiner Sicht glänzende Aussichten für interessante Press Releases in den kommenden Wochen und somit hoffentlich noch weiter steigenden Kursen.

[pflicht]

Ich sitze auch schon etwas lange auf diesem Wert. Leider bin ich sehr hoch eingestiegen. Letzte Woche habe ich etwas verbilligt. Glücklich war ich bisher nicht. Auf diesem Board war bisher auch wenig los. Wegen meiner minimalen englisch kentnissen kann ich auf yahoo und ihub auch nicht alles verstehen.
Viel wird ja wegen eines buyout geschrieben.
Wäre ja toll, wenn dies geschehen würde. Allerdings scheinen mir die Vorstellungen von 1-5 USD doch sehr übertrieben.
Sollte diese Firma tatsächlich über eine wertvolle Pipeline verfügen, wäre meiner Ansicht nach schon längst ein buyout geschehen. Wie wird das hier gesehen?


pflicht

[Eltp]

Hallo Pflicht,

Freue mich einen weiteren Gesprächspartner gefunden zu haben. Bin auch schon lange in diesem Papier investiert. Vor zwei Jahre wurde die Show durch den Wegfall (FDA) des Produktes Lodraine abrupt gestoppt. Aus meiner Sicht stehen die Vorzeichen bei diesem Run deutlich besser.
Ich lese jeden Abend seit mehreren Jahren das I-Hub Board und die Aktien Research die dort gemacht wird ist wahrhaft nicht schlecht.
Im Läufe der zeit habe ich mich eine beträchtliche Anzahl der Aktien gekauft und einen Durchschnitt von ca. 7,8 US Cent. Sofern die vom CEO angekündigten Ereignisse so Eintreffen und die Abuse Resistent Technology wirklich von der FDA im fast Track Verfahren für den Vertrieb USA freigegeben wird, halte ich Kurse um die 1Dollar durchaus für realistisch.

Das interessante an der Technologie ist, dass sie nicht physikalisch, sondern pharmazeutisch wirkt. Zudem ist sie auf weitere Medikamente übertragbar und weltweit ausrollbar. Die Patente für die Abuse Resistent Technology sind für die nächsten 17 Jahre fixiert.

Ich hoffe dass die Aktie nicht übhitzt, sondern langsam und stetig weiter klettert. Gegen einen. Buyout hätte ich auch nichts einzuwenden, sofern der Preis über einem Dollar liegt...

[due-diligence]

Hallo zusammen,

Auch ich bin der Überzeugung, dass bei der Aktie noch einiges geht. Was die meisten nicht wissen ist, dass ELTP im Besitz von 10% der Firma Novel ist. Diese Firma hat mehrere Dutzend eigene Produkte im Markt. Der Wert dieses Anteils wird auf ca. 10 - 20 Mio Dollar geschätzt. Allein der Anteil an Novel würde schon 30% der aktuellen Marktkapitalisierung ausmachen. Wenn man dann noch die 20 Patente von ANDA Produkten, von denen aktuell 9 bereits im Markt vertrieben werden und die Mega Patente für die Abuse resist. Technologie einbezieht, dann sollte die Aktie bis weit über die 1 Dollar Marke gehen. Das haben offensichtlich noch nicht so viele Aktionäre verstanden - zum Glück.

[Eltp]

Der aktuelle Chart macht einen soliden Eindruck. Die ersten Fonds zeigen Interesse und legen sich das Papier ins Depot:
http://guggenheiminvestments.com/products/etf/wmcr/holdings

[due-diligence]

Excellente Nachrichten! Elite hat einen Lizenzvertrag mit Epic über die Produktion und Vermarktung von 12 patentierten Medikamenten von Elite über die kommenden 5 Jahre geschlossen. Der Vertrag enthält Minestrone Zahlungen für jedes Medikament, sowie einen prozentuale Anteil am Gewinn für Elite.

Das Investment scheint sich auszuzahlen. Schon 100% im Plus. :-)


Elite Pharmaceuticals Announces Manufacturing and License Agreement for Twelve Generic Products


Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the signing of a Manufacturing and License Agreement ("Agreement") with Epic Pharma, LLC ("Epic"). Pursuant to the Agreement, Epic will have the right to manufacture, market and sell in the United States and Puerto Rico twelve generic products owned by Elite. Of the twelve products, Epic will have the exclusive right to market six products and the non-exclusive right to market six additional products. Epic is also responsible for all regulatory and pharmacovigilance matters related to the products and for all costs related to the site transfer for all products. Pursuant to the Agreement, Elite will receive a license fee and milestone payments. The license fee will be computed as a percentage of the gross profit, as defined in the Agreement, and earned by Epic as a result of sales of the products. The license fee is payable monthly for the term of the Agreement. The first milestone payment is due on or before November 15, 2013. Subsequent milestone payments are due upon the filing of each product's supplement with the U.S. Food and Drug Administration ("FDA") and the FDA approval of site transfer for each product as specifically itemized in the agreement. The term of the License Agreement is 5 years and may be extended for an additional 5 years upon mutual agreement.
"We are delighted that Elite elected to further develop our partnership by awarding this licensing agreement to Epic for these recently acquired products. This is a natural extension of our ongoing collaboration with Elite and allows Elite to leverage Epic's ability to manufacture on a large scale," said Jeenarine Narine, President and COO of Epic.

Nasrat Hakim, President and CEO of Elite, stated, "Epic continues to be a valuable partner to us. Epic is able to provide significant manufacturing resources for making these large volume products and this will allow Elite to maximize our profit potential for our generic business while we devote our resources to the development of our abuse resistant products utilizing our proprietary technology."

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes improving off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, twelve approved products licensed to our partner Epic Pharma and pending manufacturing site transfer, and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are oral formulations of opioids for the treatment of acute and chronic pain, which address the limitations of existing oral opioids including the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

CONTACT: For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
[e-mail]
www.elitepharma.com

[pflicht]

Hallo

der November 2013 sollte ja einige Informationen bringen, soweit ich es auf dem iHub herauslesen kann.
Kann mir jemand sagen, was es mit den "Abuse" -Entwicklungen auf sich hat. Scheinbar gilt diesen Entwicklungen das große Interesse.
Pfizer sollte gescheitert sein mit einem gleichen Präparat.
Leider kriege ich diese Geschichte nicht auf die Reihe und kann nur
Vermutungen anstellen.
Hoffe auf einen Durchbruch. Der neue CEO bekommt 170 Mill Aktien, dafür, daß er einige Entwicklungen mitbringt. Scheint mir doch etwas
schräge zu sein.

Hoffe es gibt keine bösen Überraschungen.

Gruß
Pflicht

[pflicht]

Einen kleinen Schub nach oben hat es im Dezember gegeben.
Immerhin nähere ich meinen Einstiegskursen.
Gibt es noch Interesse hier? - Es ist sehr ruhig.

pflicht

[dottore]

heutige Meldung sollte weiter Schub für den Kurs bringen

[dottore]

hier der link
http://www.nasdaq.com/press-release/elite-pharmaceuticals-in…

[dottore]

ach wie schön. Gestern eingestiegen und heute 30% hoch. Das ist eine Entschädigung für dies und das und jenes und ....

[dottore]

Vergessene oder übersehene Biotec-Perle, denn
http://www.elitepharma.com/investor_relations.asp?goto=369
wie aus der Meldung vom 14. Nov hervorgeht, haben die schon was am Markt und gerade ein Umsatzwachstum um 83% erreicht.
In der gleichen Meldung steht auch etwas, was am Kapitalmarkt zwar schon den Kurs von 7 Cent auf 18 Cent ungefähr bewegte, aber eigentlich noch keine echte Würdigung darstellt, nämlich
"Elite grants manufacturing and distribution rights to Epic in relation to the 12 approved ANDA’s acquired by Elite in August 2013. Epic will have exclusive licenses to 6 of these approved ANDA’s and non-exclusive licenses to the remaining 6 approved ANDA’s. Pursuant to this agreement, Elite will receive various milestone payments and profit splits from sales of these products. Elite expects this agreement to begin generating revenues during the quarter ended December 31, 2013."

Man kann sagen, dieser Wert wurde gerade erst entdeckt und der gestrige doch starke Kursanstieg ist erst der Anfang. Weil der Kurs so sehr stark gestern stieg, muss auch mit einem Rücksetzer gerechnet werden. Aber eine Verdreifachung vom heutigen Wert aus, sollte noch im ersten Halbjahr 2014 drin sein.
Deshalb werde ich heute und morgen schauen, ob ich umschichte und nachlege - auch wenn der Kurs weiter steigt, nein ganz besonders, wenn er steigt.

In der Meldung vom November steht nämlich noch etwas vielversprechendes

“In addition to launching a new product and substantially increasing our revenues, we have set in motion several initiatives that will have significant impact on Elite’s future”, commented Nasrat Hakim, President and CEO of Elite. “During this quarter, we acquired 12 new approved products, greatly accelerated the development of our abuse resistant technology and are on schedule for clinical trials to begin this year.”

Wenn ich das richtig verstehe, geht es um bereits zugelassene Medikamente, die mit der Elite-Galenik sicherer gegen Mißbrauch auf den Markt gebracht werden sollen.
Damit ergibt sich eine Analogie zu Oramed. Und was das für den Kurs bedeutet, haben wir da gerade erlebt.
Dort war die Verfünffachung des Kurses das Ende der Übertreibung. Hier wäre also ein Kursziel von 1,50$ das Ende der Übertreibung. Danach könnte sich der Kurs zwischen 60 und 110 Cent einpendeln.

Viel Glück
Und hier seid ihr relativ frühzeitig mit dabei, wenn ihr diese Woche einsteigt.

[dottore]

Nach dem rasanten Anstieg gestern, ist ein Minus von 15-16 % als erwartete Nachkaufgelegenheit zu interpretieren. Hab ich jedenfalls. Habe bei 23 Cent aufgestockt.

[dottore]

im Dreimonatlichen Durchschnitt werden von diesem Wert knapp über 2 Mio Stücke täglich gehandelt. Heute sind es bereits knapp 10 Mio.

Das liegt einerseits daran, dass viele durch den starken Anstieg auf den Wert aufmerksam geworden sind, andererseits daran, dass es schnelle Gewinne gab, die auch mitgenommen werden. (Hätte man gestern zum Handelsschluss machen sollen, hab ich aber auch nicht. Und dass, obwohl ich mit dem Rücksetzer gerechnet habe)

[dottore]

vor kurzem ging der Kurs bis 21 Cent runter und ist schon wieder über 22 Cent.
Da kommen Zweifel, aber ich habe mich entschieden. Vielleicht lege ich noch einmal welche dazu, wenn der Kurs die 20 Cent streift.

[dottore]

Ja, ja! Jetzt bin ich mit meinem Nachkauf auch im Plus. 0,4 Cent
Die Freude ist denn auch mehr der richtigen Einschätzung gezollt als dem Gegenwert in Cent. Und dennoch, dachte ich doch, dass der Kurs bis 22 zurückkommen könnte, hatte aber Angst, dann keine mehr zu kriegen. Somit habe ich zu 23 zugeschlagen. Die darauf folgende Verunsicherung habe ich hier einfach mal gepostet.

Wenn die heute schon ins Plus läuft, ärgere ich mich noch darüber, dass ich nicht bei 21 ein zweites Mal zugelegt habe, statt mich über den Gewinn zu freuen. Blöd, gell

[dottore]

die Richtung stimmt. schon 300% seit Oktober. Da braucht man Mut um noch dazu zu steigen, aber die Nachrichten, wie ich sie weiter oben noch mal postete, sollten doch mindestens noch eine Verdopplung ermöglichen. Vielleicht einen Hype, wie bei Oramed (mit Absturz auf dann noch das doppelte von heute.

[dottore]

wieder Höchstkurse und schöne Umsätze. Dies ist heute mein Freudeträger.
Ich beobachte einige Biotecs, die steigen, und die ich habe stagnieren, außer dieser und Genvec

[dottore]

funzt net von wegen neue Diskussion erstellen.
Deshalb erstmal hier


Da aber von anderen Teilnehmern hoch interessante Beiträge in dem Thread sind, sollte man den zumindest mal überfliegen
http://www.wallstreet-online.de/diskussion/1166376-81-90/kur…
Leider ohne Quellenangabe hat due-diligence auf eine 10%-Beteiligung an der Firma Novel hingewiesen.
Die Patende sollten direkt aus den Nachrichten bekannt sein.
http://www.finanznachrichten.de/nachrichten-aktien/elite-pha…
Hier fällt auf, dass der Kursanstieg zeitgleich durch eine Promotionsaktion und gute entstand.
Der Kursrücksetzer am Freitag war aus beiden Gründen zu erwarten. In der kommenden Woche wird sich zeigen, ob nachhaltig Vertrauen gewonnen werden konnte.
Ich meine das der Gehalt der Meldungen deutlich überwiegen müsste, revediere aber mein Kursziel nach unten, auf 40 - 60 Cent in den kommenden 2 Monaten.

[mucor]

!

Dieser Beitrag wurde von CloudMOD moderiert. Grund: auf eigenen Wunsch des Users

[mucor]

!

Dieser Beitrag wurde von CloudMOD moderiert. Grund: auf eigenen Wunsch des Users

[mucor]

Antwort auf Beitrag Nr.: 46.318.697 von mucor am 27.01.14 20:30:27

Bitte die Moderatoren meine letzten zwei Beiträge zu löschen."Danke"

[mucor]

Etwas muß ich doch noch loswerdenas ist die größte "Drecksaktie,die ich je erlebt habe(Außer Sino Forest).Manipulation Pur!

[dottore]

bei allem Respekt, wundere ich mich über deine Meinung.
Ich bin leider erst sehr spät auf die Aktie aufmerksam geworden und in der Zeit hat sie sich eigentlich ziemlich meinen Erwartungen entsprechend entwickelt. Etwas weniger, aber insgesamt recht gut. Habe auch heute noch mal zu 0,2879 zugeschlagen, weil ich mich entschieden habe, zu meiner Meinung zu stehen. Und meine Meinung ist, dass hier noch richtig was geht. Vorerst nur 100 % auf etwa 60 Cent und mehr, wenn die angekündigten Projekte konkret werden.
Nicht vergessen: Neues Management. Vielleicht war deine Erfahrung, mucor, dem vorangegangenen Management geschuldet?

[dottore]

nicht einmal einen Monat später haben wir intraday 55 Cent gesehen. Schön zu sehen, wie die Einschätzungen zu Tatsachen werden.